Fraunhofer USA Center Mid-Atlantic, Biotechnology Division (CMA-BT)

Virus-like particles displaying an antigen of Borrelia burgdorferi, the causative agent of Lyme disease (nm: nanometers).

CMA-BT has expertise and experience in biotechnology, primarily, though not exclusively, emphasizing human health applications. Scientists at the Division have engineered novel molecular designs for vaccine candidates and developed expression platforms for the production of recombinant proteins, including vaccine antigens, antibodies and other therapeutic and diagnostic molecules. Lead vaccine and therapeutic targets have progressed into clinical trials, working extensively with U.S. Government, not-for-profit and industry partners. The Division has also developed formulations of selected vaccine targets with improved stability, immunogenicity and efficacy.

Additional areas of expertise are in the engineering of cell culture systems for the production of recombinant proteins and secondary metabolites, optimized hydroponic growth systems for plant biomass production, and the generation and screening of microbial libraries for molecules with novel activities.

Scientific staff at the Division have expertise in molecular biology, protein biochemistry, immunology, virology, microbiology and plant biology, and the Division also has pilot scale production capabilities under cGMP with associated quality control and quality assurance functions.

The Division is focused on working with partners and clients to solve problems and overcome roadblocks on the path to developing novel technologies and progressing target molecules to the clinic and market. Scientist at the Center are particularly experienced in engineering molecules and pathways, developing assays, formulating lead targets for improved stability and efficacy, scaling processes and producing and releasing material under GMP.